Why Applied DNA Sciences (APDN) Stock Is Rising
Benzinga (Tue, 01-Apr 12:05 PM)
Applied DNA Sciences Inc (NASDAQ:APDN) shares are trading higher by 6.0% to $1.76 during Tuesday’s session after the company announced it positioned its TR8 PGx testing as pre-emptive testing for therapeutic safety.
What To Know: Applied DNA Sciences on Tuesday announced that its subsidiary, Applied DNA Clinical Labs (ADCL), is refining its TR8 PGx pharmacogenomics testing service by offering specialized subpanels for specific medical conditions.
The first subpanel targets patients with DPYD gene variants, which can affect metabolism of chemotherapy drugs fluorouracil (5-FU) and capecitabine (Xeloda), ...
